# Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma

> **NCT07706985** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 566 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** Toripalimab combined with Nimotuzumab
- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT07706985
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2030-07-20
- **Final completion:** 2033-07-20
- **Target enrollment:** 566 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706985, "Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07706985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*